Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

Allogene Therapeutics, Inc. (NASDAQ: ALLO ) is pioneering the development of allogeneic chimeric antigen receptor T-cells (CAR-Ts) for the treatment of cancer and autoimmune diseases. In other words, Allogene is genetically modifying immune cells (T-cells), obtained from healthy donors, inOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineering, with +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs. As an investor, I have bee ...